- Home
- BLTE vs BLSH Comparison
BLTE vs BLSH Comparison
Compare BLTE & BLSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BLTE | BLSH |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 5.8B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | BLTE | BLSH |
|---|---|---|
| Price | $158.49 | $37.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $198.00 | $51.91 |
| AVG Volume (30 Days) | 117.4K | ★ 954.6K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $64.30 |
| Revenue Next Year | $492.11 | $17.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $56.68 | $24.69 |
| 52 Week High | $200.00 | $74.98 |
Technical Indicators
Market Signals| Indicator | BLTE | BLSH |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 46.10 |
| Support Level | $157.63 | $37.42 |
| Resistance Level | $161.28 | $40.58 |
| Average True Range (ATR) | 6.26 | 2.35 |
| MACD | -1.15 | -0.58 |
| Stochastic Oscillator | 17.27 | 21.39 |
Price Performance
Historical ComparisonAbout BLTE Belite Bio Inc
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
About BLSH Bullish Ordinary Shares
Bullish is an institutionally focused global digital asset platform focused on providing market infrastructure and information services. Its objective is to provide mission critical products and services that are designed to help institutions grow their businesses, empower individual investors, and drive the adoption of stablecoins, digital assets, and blockchain technology. It expanded its product offering to provide trusted insights, authoritative news, data, indices and transparent analysis to the digital assets industry while facilitating partnerships, investment opportunities, and community engagement through its flagship Consensus conference.